Industry Recap | Global Biotech Snapshot

2025 saw renewed M&A activity, rising regulatory complexity, and increasingly sophisticated biologics portfolios. Investment in advanced modalities such as ADCs and bioconjugation platforms also continued throughout the year.

As competition intensifies and therapies become more complex, reliable CDMO partners are essential to support scalable manufacturing and consistent supply, helping ensure timely access to innovative treatments.

In this evolving landscape, execution, scale, and supply reliability continue to define long-term success.